p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer

British Journal of Cancer

Volumn 76, Issue 1, 1997, Pages 44-51

  Vega, F J ^a   Iniesta, P ^a   Caldes T ^b   Sanchez A ^b   Lopez J A ^b   De Juan, C ^a   Diaz Rubio, E ^b   Torres, A ^b   Balibrea, J L ^b   Benito, M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Lung tumours; p53 alterations; Prognostic factors

Indexed keywords

DNA; PROTEIN P53;

ADULT; ARTICLE; CANCER SURVIVAL; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 8244225811     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.334     Document Type: Article

References (39)

1. Banks L, Matlashewski G and Crawford L (1986) Isolation of human p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534
2. Blin N and Stafford DW (1976) A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 3: 2303-2308
3. Bourdon JC, D'Errico A, Paterlini P, Grigioni W, May E and Debuire E (1995) p53 protein accumulation in European Hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 108: 1176-1182
4. Brambilla E, Gazzeri S, Moro D, De Fromentel CC, Gouyer V, Jacrot M and Brambilla C (1993) Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143: 199-220
5. Carbone DP (1994) Molecular biology in the diagnosis and therapy of lung cancer. In ASCO Educational Book, pp. 322-332. American Society of Clinical Oncology: Chicago, IL
6. Chiha I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC and Minna JD (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603-1610
7. Claire YF and Fisher DE (1995) p53: from molecular mechanisms to prognosis in cancer. J Clin Oncol 13: 808-811
8. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced GI arrest. Cell 76: 1013-1023
9. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993) WAF1. a potential mediator of p53 tumor suppression. Cell 75: 817-825
10. Finlay CA (1992) p53 loss of function-implications for the processes of immortalization and tumorigenesis. Bioessays 14: 557-560
11. Fong KM, Kida Y, Zimmerman PV, Ikenaga M and Smith PJ (1995) Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res 55: 4268-4272
12. Fujino M, Dosaka-Akita H, Kato M, Kinoshita I, Akie K and Kawakami Y (1995) Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. Am J Clin Pathol 104: 319-324
13. Gandini D, Moretti S, Latorraca A, De Angeli C, Lanza K, Cuneo A, Castoldi G and del Senno L (1996) p53 exon 5 mutations in two cases of leukemic mantle cell lymphoma. Cancer Genet Cytogenet 86: 120-123
14. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B and Liebermann DA (1995) p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 10: 2263-2270
15. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ. Cunningham J, De Vries EMG, Fovach JS and Sommer SS (1995) p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 10: 681-688
16. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda Y and Takahashi T (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1-4
17. Hsu SM, Raine L and Fanger H (1981) The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase technique: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580
18. Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C and Vogelstein B (1991) Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711
19. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB (1992) Wild-type p53 in a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495
20. Lee JS, Yoon A, Kalapurakal SK, Ro JR, Lee JJ, Tu N, Hittelman N and Hong WK (1995) Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 13: 1893-1903
21. 6-methylguanine built into a unique site in a viral sequence. Proc Natl Acad Sci USA 81: 6271-6275
22. Milner J (1995) Flexibility: the key to p53 function?. TIBS 20: 49-51
23. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shiravakusa T (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 85: 2018-2023
24. Momand J, Zambetti GP, Olson DC, George DL and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245
25. Mountain CF (1986) A new international staging system for lung cancer. Chest 89 (Suppl.): 225-233
26. Orita M, Suzuki Y, Sekiya T and Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879
27. Passlick B, Izbicki JR, Riethmüller G and Pantel K (1994) p53 in non-small cell lung cancer. J Natl Cancer Inst 86: 801-802
28. Passlick B, Izbicki JR, Häussinger K, Thetter O and Pantel K (1995) Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small cell lung cancer. J Thorac Cardiovasc Surg 109: 1205-1211
29. Quinlan DC, Davidson AG, Summers CL, Warden HE and Doshi HM (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831
30. Ryberg D, Kure E, Lystad S, Skaug V, Stangeland L, Mercy I. Borrensen AL and Haugen A (1994) p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res 54: 1551-1555
31. Sanger F, Nicklen S and Coulson AR (1977) DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74: 5463-5467
32. Scheffner M, Bruce AW, Huibregtse JM, Levine AJ and Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
33. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ (1996) Relationship between p53 gene abnormalities and other tumour characteristics in breast cancer prognosis. In J Cancer 69: 135-141
34. Shipman R, Schraml P, Colombi M, Raefle G, Dalquen P and Ludwig C (1996) Frequent TP53 gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung cancer. Eur J Canter 32A: 335-341
35. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM and Fornace AJ (1995) Involvement of the p53 tumor suppressor in repair of U.V.-type DNA damage. Oncogene 10: 1053-1059
36. Sobin LH (1982) The World Health Organization's histological classification of lung tumors: a comparison of the first and second editions. Cancer Detect Prev 5: 391-406
37. Top B, Mooi WJ, Klauer SG, Boerrigter L, Wisman P, Elbers M, Visser S and Rodenhuis S (1995) Comparative analysis of p53 gene mutations and protein accumulation in human non-small cell lung cancer. Int J Cancer 64: 83-91
38. Travis WD, Travis LB and Devesa SS (1995) Lung cancer. Cancer 75: 191-202
39. Ullrich SJ, Anderson CW, Mercer WE and Appella E (1992) The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 267: 15259-15262